版本:
中国

BRIEF-Nuvo Pharmaceuticals says European ankle sprain study with Pennsaid 2 pct failed to meet primary endpoint

May 15 Nuvo Pharmaceuticals Inc

* Nuvo Pharmaceuticals Inc announces topline results from European ankle sprain study with Pennsaid 2 pct

* Nuvo Pharmaceuticals Inc - trial had failed to meet its primary endpoint

* Nuvo Pharmaceuticals - will continue to assess opportunities available to pursue marketing authorizations for Pennsaid 2 pct in Canada, Australia and E.U.

* Nuvo Pharmaceuticals - will be reviewing trial results in with its scientific advisors and regulatory consultants to determine what its next steps should be Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐